Short radiation with chemo and immunotherapy for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new approach for locally advanced rectal cancer. You'll receive a short course of radiation, then chemotherapy plus an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination shrinks the tumor enough to avoid surgery or improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rectal cancer that has grown into or through the rectal wall or spread to nearby lymph nodes.
- The tumor is within about 10 cm of the anal opening.
- You are in fairly good health (able to do light work or be up and about most of the day).
- Your blood counts and liver/kidney tests are within a safe range.
- You have not had prior radiation to the pelvis or treatment for this cancer.
- You do not have an autoimmune disease, active infections, or conditions that raise your risk of bowel perforation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests whether a short course of radiation followed by an immunotherapy drug (PD-L1 inhibitor) plus chemotherapy works as well as or better than a longer radiation course for locally advanced rectal cancer. The goal is to shrink tumors before surgery.
This trial tests a shorter course of radiation before chemotherapy and an immunotherapy drug to shrink mid-to-lower rectal cancer that has not spread. The goal is to improve treatment response and reduce side effects, potentially allowing for less invasive surgery.
This trial tests a new combination for locally advanced rectal cancer: adding a cholesterol-lowering drug plus an immunotherapy drug to the standard chemotherapy and radiation before surgery. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
Hear when a new Rectal Neoplasms Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.